tiprankstipranks
Trending News
More News >
ReposiTrak (TRAK)
NYSE:TRAK
US Market

ReposiTrak (TRAK) Earnings Dates, Call Summary & Reports

Compare
141 Followers

Earnings Data

Report Date
May 18, 2026
After Close (Confirmed)
Period Ending
2026 (Q3)
Consensus EPS Forecast
0.09
Last Year’s EPS
0.1
Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings

Earnings Call Summary

Q2 2026
Earnings Call Date:Feb 17, 2026|
% Change Since:
|
Earnings Call Sentiment|Positive
The call emphasized durable progress: steady revenue growth (7% Q2, 8% YTD), meaningful margin expansion (income from operations +34% Q2, +31% YTD), strong balance sheet (≈$28.7M cash, zero bank debt), continued share repurchases, dividend increases, and strategic investment in patented Touchless Traceability and AI-powered detect-and-correct capabilities. Key challenges center on high supplier data error rates (50%–70%), slower-than-ideal supplier onboarding that limits near-term Traceability revenue (currently ~8%–10%), an anticipated permanent step-up in effective tax rate (~20%), and some SG&A pressures. On balance the company presented multiple material positives (recurring revenue conversion, profitability, cash returns, IP moat, RTN scale) that outweigh the operational and market headwinds.
Company Guidance
Management's guidance emphasized continued SaaS conversion, capital returns and disciplined spending: since 2020 they converted >$7M of one‑time revenue to recurring and grew recurring revenue from 62% to >98%, paid down >$6M of bank debt, cut annual operating expense from ~$19M to $16M and expanded net margin from 8% to north of 30%; near‑term financials showed Q2 revenue +7% to $5.9M, Q2 operating income +34% to $1.8M, Q2 GAAP net income $1.7M (EPS $0.09 on 18.2M basic / 19.1M diluted), FYTD revenue +8% to $11.8M and FYTD operating income +31% to $3.7M. They expect a ~20% effective tax rate going forward, no meaningful incremental cash OpEx or CapEx for AI/patent work, continued balance‑sheet strength (net cash up from $13.7M in 2020 to ~ $29M in 2025 with $28.7M cash and 0 bank debt), ongoing buybacks (Q2 repurchased ~80k shares for $1.1M; 2.22M total repurchased for $14.5M; ~$6.7M authorization remaining), preferred redemptions at ~$750k/quarter with ~196k shares (~$2.1M) left targeted to be retired by Dec 2026, a quarterly dividend of $0.02 (third consecutive 10% raise) and a goal to return ~50% of annual cash from operations to shareholders while preparing for FDA‑driven acceleration of Traceability onboarding (~18 months to the deadline by year‑end).
Recurring Revenue Transformation
Since 2020 the company converted over $7.0M of one-time revenue to recurring SaaS, increasing recurring revenue from 62% of total revenue to over 98%.
Top-Line Growth
Q2 fiscal 2026 revenue increased 7% year-over-year from $5.5M to $5.9M; fiscal 2026 year-to-date revenue increased 8% from $10.9M to $11.8M.
Profitability Expansion
Income from operations rose 34% year-over-year to $1.8M (from $1.4M). GAAP net income for Q2 increased 9% to $1.7M (from $1.6M). GAAP net income to common shareholders rose 13% to $1.6M (from $1.5M).
Earnings Per Share Improvement
Q2 EPS was $0.09 basic and diluted; year-to-date EPS was $0.19 basic and $0.18 diluted — a 13% increase versus the comparable period last year.
Operating Expense Discipline
Total operating expenses for the quarter decreased 2% despite continued investment in RTN and product development; fiscal year-to-date operating expenses were essentially flat year-over-year ($8.1M vs $8.1M).
Balance Sheet Strength and Cash Generation
Net cash compounded annual growth rate of 16% since 2020; net cash grew from $13.7M in 2020 to almost $29M in 2025. Total cash was $28.7M at Dec 31, 2025 and the company reported zero bank debt.
Capital Return to Shareholders
Repurchased ~80k common shares in Q2 for $1.1M (avg $13.75); total repurchases since inception are 2.22M shares for $14.5M (avg $6.52). Approximately $6.7M remains under the $21M buyback authorization. Declared quarterly dividend of $0.02/share (third 10% increase since 2022).
Preferred Stock Retirement
Redeemed 70k preferred shares in Q2 for $750k; total preferred redeemed ~642k shares for $6.9M, with 196k preferred shares (≈$2.1M) remaining and a stated plan to redeem remaining shares by Dec 2026 at current cadence.
Product & IP Investment
Filed two patents (Touchless Traceability and data-identification/auto-correction method) adding to a portfolio of 9 U.S. patents; continued investment in AI and modernization of core stack with limited expected incremental cash spend.
Traceability Network Scale and Technical Advantage
ReposiTrak claims industry-leading ReposiTrak Traceability Network (RTN) with nearly 2M records and a growing queue to join. Company highlighted proprietary detect-and-correct AI (500+ detection algorithms, self-learning) that can auto-correct many supplier data errors, creating a competitive moat.

ReposiTrak (TRAK) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

TRAK Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
May 18, 2026
2026 (Q3)
0.09 / -
0.1
Feb 17, 2026
2026 (Q2)
0.09 / 0.09
0.0812.50% (<+0.01)
Nov 13, 2025
2026 (Q1)
0.09 / 0.09
0.0812.50% (<+0.01)
Sep 29, 2025
2025 (Q4)
0.09 / 0.09
0.0812.50% (<+0.01)
May 15, 2025
2025 (Q3)
0.09 / 0.10
0.0825.00% (+0.02)
Feb 12, 2025
2025 (Q2)
0.09 / 0.08
0.0714.29% (<+0.01)
Nov 14, 2024
2025 (Q1)
- / -
0.07
Sep 30, 2024
2024 (Q4)
0.08 / 0.08
0.0714.29% (<+0.01)
May 15, 2024
2024 (Q3)
- / 0.08
0.080.00% (0.00)
Feb 14, 2024
2024 (Q2)
0.06 / 0.07
0.0616.67% (+0.01)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

TRAK Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Feb 17, 2026
$10.09$9.20-8.82%
Nov 13, 2025
$15.00$15.04+0.27%
Sep 29, 2025
$16.54$14.82-10.39%
May 15, 2025
$22.86$22.36-2.18%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does ReposiTrak (TRAK) report earnings?
ReposiTrak (TRAK) is schdueled to report earning on May 18, 2026, After Close (Confirmed).
    What is ReposiTrak (TRAK) earnings time?
    ReposiTrak (TRAK) earnings time is at May 18, 2026, After Close (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is TRAK EPS forecast?
          TRAK EPS forecast for the fiscal quarter 2026 (Q3) is 0.09.